The reduction in Acorn's stake to just below 5% suggests a continued passive exit. Monitor for further 13G amendments or a potential conversion to 13D if the investor's intent changes.
Price Chart
Executive Summary
Acorn Bioventures, L.P. and affiliated entities filed an amended Schedule 13G disclosing an aggregate beneficial ownership of 1,021,668 shares (4.5%) of Karyopharm Therapeutics Inc. as of October 2, 2026, down from prior filings. The filing is an amendment reflecting a reduced stake, signaling a passive exit from a previously larger position.
Key Financial Metrics
Key Facts
- Acorn Bioventures, L.P. reported 429,101 shares (1.9%) as of October 2, 2026.
- Acorn Bioventures 2, L.P. reported 592,567 shares (2.6%) as of the same date.
- Combined beneficial ownership across all reporting persons is 1,021,668 shares (4.5%).
- The stake is calculated based on 22,681,460 shares outstanding as of June 30, 2026.
- This is an amendment to a prior Schedule 13G filing, indicating a reduction from a previously larger position.
Financial Impact
Acorn entities now hold 4.5% of KPTI, down from a prior higher stake; no specific prior percentage or dollar value provided in the filing.
Risk Factors
- Further selling by Acorn could pressure the stock.
- The reduced stake may signal waning institutional confidence in Karyopharm's near-term prospects.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001636587-26-000086 |
| Document: 0001636587-26-000086-index.html | 0001636587-26-000086 |
| Document: 0001636587-26-000086.txt | 0001636587-26-000086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.5175 | awaiting T+60 | — | $0.4820 (+6.86%) |
Oct 14, 2026 13d ago | 8-K | $0.3150 | awaiting T+60 | — | $0.4820 (+53.02%) |
Oct 8, 2026 19d ago | SC 13G/A | $0.6000 | awaiting T+60 | — | $0.4820 (+19.67%) |
Sep 25, 2026 4w ago | SC 13G/A | $1.62 | awaiting T+60 | — | $0.4820 (−70.25%) |
Sep 25, 2026 4w ago | SC 13G/A | $1.62 | awaiting T+60 | — | $0.4820 (−70.25%) |
Sep 11, 2026 6w ago | 8-K | $1.61 | awaiting T+60 | — | $0.4820 (+70.06%) |
Aug 31, 2026 8w ago | 8-K | $2.06 | awaiting T+60 | — | $0.4820 (−76.60%) |
Aug 13, 2026 10w ago | 8-K | $1.99 | awaiting T+60 | — | $0.4820 (+75.78%) |
Aug 10, 2026 11w ago | Press Release | $1.96 | awaiting T+60 | — | $0.4820 (−75.41%) |
Jul 31, 2026 12w ago | 8-K | $1.92 $0.4821 | ▼ −74.89% | ▼ −77.35% | $0.4820 (−74.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers